Here are the biggest CBD news stories from this week:
Dillard’s is now selling CBD products both in its stores and online.
The department store has partnered with CBD for Life, a CBD brand based in New Jersey and owned by iAnthus Capital Holdings, Inc., to sell products in 265 of its stores in 29 states.
All of the products Dillard’s will sell are CBD topicals, including serums, cleansers, rubs, roll-ons, massage lotion, and bath bombs.
“We’re excited for our products to be featured on the shelves of one of the largest and most well-regarded fashion retailers in the United States,” said Beth Stavola, Co-Founder of CBD For Life in a press release. “The ability to reach an even broader audience via the well-established customer base of a great partner like Dillard’s brings us another step closer to achieving our end goal of establishing CBD For Life as a household name in beauty and wellness.”
Dillard’s joins a growing list of retailers who have decided to carry CBD products, including Walgreens, CVS, Kroger, and several others.
Larger stores like Target and Walmart have stated that they do not currently have plans to carry CBD products.
On Tuesday, the US Hemp Roundtable sent a 29-page report with safety data on CBD to the US Food and Drug Administration (FDA).
The Roundtable submitted its report on the deadline of the FDA’s public comment period on CBD, a channel for the public to provide data and information about the compound.
The information provided in the report includes scientific research and reports from the Hemp Industries Association along with companies and organizations that are members of the Roundtable.
Some of the most noteworthy information is about “adverse events.”
“One of our member companies sold approximately 580,000 products with zero serious adverse events reported to the company, and about 300 non-serious adverse reported for humans and animals,” states the report. “Another member company has sold over 1.4 million products, with zero serious adverse events and 623 non-serious adverse events.”
In light of all the available evidence, the Roundtable concluded the following:
“We believe that there are no unique safety concerns associated with the consumption of CBD that would preclude the use of FDA’s current regulatory framework in establishing product-specific acceptable levels of use.”
The Roundtable also offered the following recommendations to the FDA:
The FDA recently announced that it would offer another update on its progress with CBD regulations by the end of summer or in early fall.
The US Senate has scheduled a hearing entitled “Hemp Production and the 2018 Farm Bill” for next week.
The Senate Agriculture Committee will have witnesses from the USDA, the FDA, and the EPA on July 25, which suggests the discussion will center around hemp production regulations.
Both the FDA and USDA are currently working on regulations for CBD and hemp, respectively.
The USDA has stated that it plans to release its interim final rule on hemp in August, in time for the 2020 growing season.
Dr. Abernethy of the FDA has stated that the agency is “expediting” its regulatory process on CBD.
Governor of Colorado Jared Polis and USDA official William Richmond are planning to speak at the American Herbal Products Association’s (AHPA) first-ever CBD and hemp conference next month.
Gov. Polis, a former Congressman, is a long-time hemp supporter.
Mr. Richmond, a senior marketing specialist for the USDA Agricultural Marketing Service, is scheduled to give an update on the status of the USDA’s hemp regulations.
According to the AHPA’s announcement of the event, the FDA has committed to giving an update on its regulatory framework for CBD as well.
The purpose of the two-day conference is “to provide critical information for companies navigating the rapidly evolving legal, regulatory and financial landscapes to manufacture and market dietary supplement products with hemp or hemp-derived ingredients including cannabidiol (CBD).”
These are the topics to be discussed:
The event will be held in Denver at Crowne Plaza on August 15-16.
After a report last week that legislation to legalize CBD products and hemp had stalled in the Ohio House, the bill has passed and sits on Gov. Mike DeWine’s desk.
The bill will allow farmers to grow hemp once the Ohio Department of Agriculture draws up rules and regulations, and it also permits the sale of CBD products.
Senate Bill 57 unanimously passed in the Ohio Senate in late March.
It was not until June that the measure was voted on in a House committee and passed to the House floor.
Last week, the Speaker of the House Larry Householder (R-Glenford) said the bill had stalled and would not be discussed again until the fall at the earliest.
However, SB57 passed the House on Wednesday by a vote of 89-3, sending the bill back to the Senate because of new amendments made to it.
The Senate unanimously concurred the same day, sending the bill to Gov. DeWine.
Ohio is one of only four states left that have yet to legalize and implement a hemp production program.
Both farmers and universities stand to benefit directly from the bill.
“Farmers are getting hit pretty hard right now with the weather and things — the tariffs and the weather,” said Householder. “I think that it now can help them a little bit. It certainly can help universities like Ohio State University, as they continue to study hemp and try to perfect seeds and such.”
Gov. DeWine is expected to sign the bill, and if he does, it will go into effect immediately.